Croop R, Lipton RB, Kudrow D, et al. - For the preventive treatment of migraine, researchers compared the effectiveness of rimegepant with placebo via a multicentre, phase 2/3, randomized, double-blind, placebo-controlled trial at 92 sites in the US. Of 1,591 participants assessed for eligibility, 747 were randomized to receive either rimegepant 75 mg (n = 373) or matching placebo (n = 374) every other day for 12 weeks. Outcomes support the effectiveness of rimegepant for preventive treatment of migraine. Its tolerability was noted to be comparable to that of placebo, and there appeared no unexpected or serious safety issues. On the primary endpoint of change in the mean number of migraine days per month during weeks 9–12, rimegepant was better than placebo. There were 133 (36%) of 370 patients who received rimegepant that reported an adverse event vs 133 (36%) of 371 who received placebo.